What precision dx are available for stage 4 pancreatic cancer, esp with kras mutation
For stage 4 pancreatic cancer, especially with a KRAS mutation, there are several precision diagnostic tests available that can help guide treatment decisions. However, it's important to note that guidelines may have some limitations regarding the latest advancements for this specific scenario.
According to the National Comprehensive Cancer Network (NCCN) Guidelines for Pancreatic Adenocarcinoma (Version 2.2022), the following biomarker testing is recommended:
-
Testing for mismatch repair deficiency or microsatellite instability for patients with metastatic disease to guide the use of pembrolizumab.
-
Broad molecular profiling, including testing for KRAS mutations, is recommended for patients with good performance status where the results could guide future treatment options.
The NCCN states that KRAS mutations are found in over 90% of pancreatic adenocarcinomas and are associated with a more aggressive biology. However, KRAS mutations alone are not currently actionable for FDA-approved therapies.
From the American Society of Clinical Oncology (ASCO), some additional insights:
-
Testing pancreatic cancer tissue for specific genetic mutations, including KRAS, is recommended to help determine if a patient may benefit from a clinical trial studying a targeted therapy.
-
While KRAS mutations are very common in pancreatic cancer, directly targeting mutant KRAS has proven difficult so far. However, there is ongoing research into therapies that may work in KRAS-mutated cancers indirectly.
In summary, while KRAS mutation testing is recommended for pancreatic cancer to explore clinical trial options, there are currently no FDA-approved precision therapies specifically for KRAS-mutated pancreatic cancer outside of a trial setting. Testing for other biomarkers and broad molecular profiling is also advised per guidelines to evaluate potential treatment options.
Your next question, already answered
Tap to keep going. 2 free answers, then a free account.
Ask Navis about your case
That answer is general. Ask about your specific situation. Answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Sources & medical oversight
- Grounded in NCCN Guidelines for Patients: Pancreatic Cancer — the same guidelines oncologists use.
- Built by OpenCancer’s team of physician-scientists and cancer survivors.
- Last updated October 15, 2025. Informational only — not a substitute for your oncology team.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Source Guidelines
NCCN Guidelines for Patients: Pancreatic Cancer (2026)Browse all NCCN Guidelines for Patients →Related Services
Services that may help with diagnosis for Pancreatic Cancer patients
Have your records handy? Add them to a private case for a deeper, personalized read →
More questions about Pancreatic Cancer
- How do I know if my Pancreatic Cancer has an actionable mutation
- What is a cancer vaccine and is one available for Pancreatic Cancer
- What targeted therapies are available for Pancreatic Cancer
- What does TP53 mutation mean for Pancreatic Cancer prognosis
- What does BRAF V600E mutation mean for my Pancreatic Cancer
- What does EGFR mutation mean for Pancreatic Cancer treatment
- Which biomarker tests (KRAS, BRCA1/2) are recommended for my Pancreatic Cancer, and how will the results guide my...
- What genetic mutations are commonly found in Pancreatic Cancer